Skip to main content

Advertisement

Table 1 Clinicopathological data of patients with and without RTEL1 and ABCA13 amplification

From: Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma

  RTEL1 CNV p-value ABCA13 CNV p-value RTEL1 and ABCA13 amplification p-value
  ≥3 copies Others   ≥3 copies Others   Present Absent  
Gender          
 Male 32 53 0.987 38 42 0.003* 17 61 0.031*
 Female 15 25   7 30   2 34  
Age          
 ≤50 years 8 27 0.034* 10 21 0.408 2 29 0.074
 >50 years 39 51   35 51   17 66  
Histopathology          
 Intestinal 36 46 0.045* 34 43 0.079 15 61 0.214
 Diffuse 11 32   11 29   4 34  
Localization          
 Cardia 12 12 0.197 9 15 0.901 4 19 0.969
 Non-cardia 35 63   35 55   15 73  
Stage          
 I–II 17 37 0.218 16 34 0.215 4 43 0.05*
 III–IV 30 41   29 38   15 52  
pN          
 N0 9 19 0.395 5 19 0.033* 2 23 0.157
 N1 or more 37 53   39 48   17 67  
pT          
 T1–T3 34 62 0.359 36 53 0.431 13 74 0.375
 T4 13 16   9 19   6 21  
pM          
 M0 10 15 0.746 10 13 0.741 4 17 0.360
 M1 12 15   13 14   8 18  
  1. M male, F female, pN lymph node metastasis status, N0 without lymph node metastasis, N1 or more metastasis in one ore more lymph nodes, pT extent of the primary tumor, T1–T3 without serosal extravasation, T4 with serosal extravasation, pM, distant metastasis status, M1 with distant metastasis, M0 without distant metastasis. *Significant difference between groups with and without amplification, p ≤ 0.05, Chi-square test